Developed under the direction and sponsorship of Gilead Sciences, Inc.
Improved HIV prevention awareness, education, and access are essential for protecting those who might benefit and helping tackle the epidemic. At what promises to be an exciting AIDS 2024 congress, Gilead is proud to sponsor an interactive and engaging symposium that aims to instil a sense of urgency around addressing the unmet needs and health inequities that exist in HIV prevention globally.
An international panel of individuals with lived experience and subject matter experts will explore the necessity of system changes; emphasise the importance of person-centered care; and spotlight the crucial use of creative solutions to address health inequities, unmet needs, and stigma. Vitally, these discussions are intended to inspire collective efforts from all attendees towards achieving the Joint United Nations Programme on HIV and AIDS (UNAIDS) 2030 HIV prevention targets and helping end the HIV epidemic together.
Across a varied agenda, the following objectives will be addressed:
- Highlight current challenges in ending the global HIV epidemic and underscore the need to drive towards the updated UNAIDS goals that now highlight the increasingly important role of HIV prevention.
- Advocate for change towards the prioritisation and normalisation of HIV prevention in public health agendas to reduce stigma and inequities, in order to end the HIV epidemic.
- Foster open dialogue about the need to reimagine HIV prevention strategies to provide person-centered options, as a critical lever in reaching global targets.
What’s Preventing Us from Preventing: Pushing Together Towards the UNAIDS 2030 HIV Prevention Goals
Wednesday July 24, 07:00–08:00 CEST, Hall B0a / Channel 4
Programme:
A combination of moderator-led panel discussion, keynote presentations, and data slide-supplemented debate, with opportunities provided for audience interaction and Q&A
- Introduction and Putting People First
- The UNAIDS 2030 HIV Prevention Goals and the Increasingly Important Role of HIV Prevention
- Addressing Barriers to Prevention
- Key Issues Associated with Prevention: Moderated Debate
- Closing Section
- Call to Action and Q&A
Hear more about this event from the meeting Chair, Senior Vice President of Public Affairs at Gilead Sciences, Alex Kalomparis
Symposium expert panel
Alex Kalomparis
Gilead Sciences
Alex Kalomparis is Senior Vice President of Public Affairs at Gilead, providing leadership in advancing the company’s commitments to corporate philanthropy, patient advocacy, community engagement and health, and Black equity. He has received several recognitions for LGBTQ leadership, including being named one of the Top 10 Inspirational Leaders at the 2021 British LGBTQ Awards.
Terrell Parker
NMAC, Washington DC, US
Terrell Parker, a proud Black gay professional from Indianapolis, Indiana, USA, boasts a decade of expertise in programme development, non-profit management, and fundraising. Parker’s tenure as Manager in the Center to End the Epidemic at NMAC involved overseeing a $7.1 million cooperative agreement with HRSA – ESCALATE. He developed and implemented ESCALATE, a programme targeting HIV-related stigma reduction in the Ryan White Care System, training and assisting over 1,500 individuals nationwide.
In February 2024, Parker assumed the role of Chief Operating Officer at Indiana Youth Group, the longest-serving LGBTQ Center in the USA, marking a new chapter in his impactful career.
Troy Sinkovic
ACON Health Limited, Sydney, Australia
Troy Sinkovic (He/Him) works at ACON Health Limited and for over 15 years has worked in gay men’s sexual health, HIV care and support, peer education programmes, social media planning, and HIV/STI testing.
Sinkovic is currently the Operations Manager for a peer-led, community-based HIV and sexually transmitted infection (STI) testing service for gay, bisexual, and other men who have sex with men (Trans and Gender Diverse Inclusive), and led ACON’s community response to Mpox in 2022/2023.
Francisco Ruiz
White House Office of National AIDS Policy (ONAP), Washington DC, USA
Francisco Ruiz is the Director of the White House’s Office of National AIDS Policy (ONAP). In this pivotal role, Francisco leads efforts to implement the nation’s strategy to addressing HIV, working closely with government agencies at all levels, community-based organizations, healthcare providers and many other entities to coordinate a comprehensive response to the HIV epidemic. Previously, Francisco served as the Senior Advisor for Program Innovation and Coordination within the Division of HIV Prevention (DHP) at U.S. Centers for Disease Control and Prevention (CDC).
His dedication and impact in the field were recognized in 2010 when he was named one of the inaugural “100 Most Influential AIDS Advocates” by POZ Magazine.
Àngel Rivero
Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Àngel Rivero is a Consultant Physician in internal medicine, and medical director at BCN Checkpoint, associated with Hospital Germans Trias i Pujol. Rivero has been working in the pre-exposure prophylaxis implementation and STI program at the community center. Rivero has participated as investigator in multiple pre-exposure prophylaxis trials, HIV cure strategies, new antibiotics against STIs, HIV vaccine trials, and other STI vaccine trials.
Vanessa Apea
Queen Mary University, London, UK
Dr Vanessa Apea has been a Consultant Physician in genito-urinary and HIV medicine at Barts Health NHS Trust, London, UK, since 2011. She is also an Honorary Senior Lecturer and Deputy Academic Lead for equality, diversity, and inclusion within Queen Mary University of London’s School of Medicine and Dentistry. Dr Apea’s work extends to Ghana and is on the research faculty for the University of Ghana Medical Centre, Africa.
Dr Apea has an established track record of exploring barriers to engagement in care in marginalised populations and has a particular research interest in participatory approaches and the intersection of race, gender, and health.
Nittaya Phanuphak
Institute of HIV Research and Innovation, Bangkok, Thailand
Dr Nittaya Phanuphak is Executive Director at the Institute of HIV Research and Innovation in Bangkok, Thailand.
She has deep interest in the establishment and sustainability of the Key Population-Led Health Services (KPLHS) which empower key population lay providers who are members of key population communities to design and co-deliver sexual health, mental health, rights, and other harm reduction services to their peers.
Dr Phanuphak provides ongoing research support to various implementation science and clinical trial studies as principal investigator or site-principal investigator. She holds a current role as the International AIDS Society (IAS) Governing Council Representative of Asia and the Pacific Islands, the Deputy Editor of the Journal of International AIDS Society (JIAS), and the Associate Editor of Sexual Health.
Not able to join us at AIDS 2024?
Please reach out to your local Gilead team for other ways in which we can share these important conversations with you.
This non-promotional meeting is organised and funded by Gilead Sciences, Inc.
Date of preparation: July 2024 | IHQ-UNB-5929
